Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

June 30, 2015

Conditions
Familial Mediterranean Fever
Interventions
DRUG

Kineret

Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.

Trial Locations (1)

52621

Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT01705756 - Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever | Biotech Hunter | Biotech Hunter